Full-Time

Associate Manufacturing Operator

Posted on 12/16/2025

Deadline 12/23/25
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

No salary listed

Athens, GA, USA

In Person

Category
Biology & Biotech (8)
, , , , , , ,
Requirements
  • High school diploma or GED.
  • Must be able to read, write, and understand Basic English and read and interpret documents such as safety rules, operating and maintenance instructions, government regulations and procedure manuals.
  • Basic math skills.
  • Ability to communicate and effectively work as part of a team.
  • Must be willing and able to meet the physical demands of this job which include: standing, walking, climbing, bending, stopping, reaching with hands and arms, and using hands to finger, handle or feel; frequently required to talk, hear, taste and smell; must have the ability to work from ladders or platforms up to 30 feet in the air and the ability to lift, push or pull up to 40 lbs.
  • Specific vision abilities required by this job include close vision, distance vision, color vision, depth perception, and ability to adjust focus.
  • Must be able to qualify for respiratory protective equipment use.
  • While working in this job the employee is frequently exposed to outside weather conditions including extreme heat and cold.
  • Must be willing and able to work overtime as needed.
  • Ability to work rotating 12-hour shifts required which may include days and/or nights, in support of continuous operations.
Responsibilities
  • The Associate Manufacturing Operator performs duties related to the preparation and manufacture of active pharmaceutical ingredients, intermediates, and/or medical devices.
  • These responsibilities include using equipment for the assembly and processing tasks to produce finished products according to established specifications and in accordance with standard operating procedures, as regulated by quality, environmental, and safety agencies (FDA, EPA, OSHA, DEA, etc.).
  • Possesses a basic understanding of a limited number of chemical production processes within area of assignment and a working knowledge of manufacturing equipment and chemical processing principles.
  • Operates and cleans production equipment used to produce intermediate or finished products for Active Pharmaceutical Ingredients, medical device raw material components, or other products as directed; Completes all associated support activities in the production of these products.
  • Interprets instructions and specifications and uses to set up equipment.
  • Follows and accurately completes batch records/logs, SAP transactions and other documentation associated with all production processes to ensure efficient operations and compliance with cGMP and standard operating procedures.
  • Demonstrates effective operation of dryers, centrifuges, mills, reactors, water systems, DCS and PLC control systems and appropriately responds to alarms and interlocks.
  • Transports materials of varying weight in accordance with established safety guidelines using material handling equipment and additional assistance as required.
  • Performs area safety inspections to identify safety hazards and report findings in accordance with company protocols.
  • Performs all duties with attention to quality, safety and environmental matters including: wearing appropriate personal protective equipment, recognizing, reporting, and appropriately responding to hazards in the work area (spills/accidents/near misses), maintaining proper housekeeping at all times, and properly labeling and storing chemicals.
  • Completes process sampling requirements following applicable schedules and techniques.
  • Demonstrates adherence to safety procedures by monitoring personal and peer behaviors, work environment and housekeeping.
  • Responsible for handling controlled substances in compliance with applicable State and local law and J&J requirement.
  • Ensures products are correctly manufactured and removes defects as required.
  • Compiles records and reports on quality inspection results.
  • Performs minor troubleshooting on equipment such as dryers and centrifuges as well as DCS/PLC controls and failure issues and recognizes abnormal operation of instrumentation.
  • Participates on site investigative teams and where applicable, in VSAs, PSSRs, PHAs, and behavioral safety assessments; Corrects and/or mitigates findings from assessments.
  • Live Our Credo and the Innovative Medicine Purpose by putting the need of Our Credo stakeholders first, pursuing the highest standards of compliance, quality and ethics.
  • Connect inclusively within the department, with other departments, and within the company to address customer needs.
  • Shape the future through innovation by inspiring new ideas, trying new things, and demonstrating resilience and agility to adapt to change.
  • Grow by developing self and others to reach goals by engaging in open and honest conversations, managing energy, and taking ownership for outcomes.
  • Additional position requirements: Assumes responsibility for the environmental effects of work performed and for the identification and recording of environmental problems as they arise.
  • Follows all applicable aspects of the site Environmental Management System as it pertains to normal job duties.
  • Partners with Supervisor and Quality Department in making recommendations to modify existing procedures, instructions and batch logs within the assigned production processes as well as developing new procedures, instructions, and batch logs.
  • Carry out duties in compliance with all state and federal regulations and guidelines including FDA, EPA, OSHA and DEA. Maintain compliance with all company and site policies and procedures and the intent of our Credo.
  • Demonstrates the ability to respond swiftly and effectively to emergency situations, executing emergency response duties that include the proficient use of a Self-Contained Breathing Apparatus (SCBA), donning a Level A fully encapsulated suit, and performing critical rescue operations.
  • Completes RCRA training within first six months of employment and annually thereafter.
  • Completes all regulatory training as assigned (cGMP, ISO14001, OSHA, DEA, etc.)
  • Completes Operator Training Program according to established guidelines.
  • Accountable to ensure the Area is prepared for internal and external audits. Participates in audits as necessary. Comply with documentation and housekeeping practices to assure a continuous state of inspection readiness.
  • Works with the team to look for ways to simplify or improve products, services, systems, and processes to achieve business goals, e.g., improve yield, cycle time, quality, and productivity.
  • Makes a positive contribution through demonstration of ability to seek out assistance from co-workers as needed, to suggest ways to improve upon current operations practices and systems; and to learn new skills, procedures and processes.
  • Be available for overtime work on a scheduled or emergency basis.
Desired Qualifications
  • A minimum of 6 months of work experience in chemical, pharmaceutical, or other industry that complies with cGMP environment is preferred
  • A minimum of 1 year experience in a regulated manufacturing industry is preferred
  • Operating skills of manufacturing equipment, tools, and hand/forks trucks preferred.
  • Knowledge of Digital Control System and SAP systems.
  • Basic PC navigation such as the ability to enter data into programs/software applications as instructed and use software applications for mail, word processing, spreadsheets and other job specific needs highly preferred.

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue hit $24.1 billion, up 9.9%, raising 2026 forecast to $100.8 billion.
  • Nipocalimab gains FDA Priority Review for autoimmune hemolytic anemia and myasthenia gravis efficacy.
  • Shockwave C2 Aero launches in US and Japan targeting 315 million calcified CAD patients.

What critics are saying

  • Stelara sales plunge 60% to $656 million in Q1 2026 post-patent expiration, creating $2.3 billion hole.
  • Icotyde stalls at 1,500 prescriptions, missing oncology targets by Q3 2026.
  • CAPLYTA faces Invega Sustenna competition, achieving under 10% adoption by mid-2027.

What makes Johnson & Johnson unique

  • J&J unites Innovative Medicine and MedTech under single brand since September 2023.
  • DARZALEX and TREMFYA dominate oncology and immunology with $57 billion pharma sales in 2024.
  • CARTO System leads electrophysiology for 30 years with AI-powered CARTOSOUND SONATA.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Company News

Yahoo Finance
Apr 14th, 2026
J&J's Spravato hits $468M in Q1 sales, signalling upside for psychedelics peers like Atai

Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.

Yahoo Finance
Apr 14th, 2026
J&J hits $100B milestone with 6.4% growth, eyes double-digit revenue by decade's end

Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.

Business Wire
Apr 7th, 2026
Johnson & Johnson launches VARIPULSE Pro in Europe with 5x faster ablation for atrial fibrillation treatment

Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.

Yahoo Finance
Apr 3rd, 2026
J&J's dividend stays resilient despite market sell-offs and healthcare challenges

Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.

Yahoo Finance
Apr 1st, 2026
J&J takes over NBTXR3 Phase III as Nanobiotix shifts to Curadigm, secures runway into early 2028

Nanobiotix has transferred full operational and financial responsibility for its NBTXR3 radioenhancer programme to Johnson & Johnson, with Phase III head-and-neck results expected in H1 2027 and Phase II lung cancer data anticipated in early 2027. The company is pivoting towards its Curadigm nanoprimer platform, filing four patents, starting GMP manufacturing and signing over 20 material transfer agreements with partners. Additional Curadigm data is expected before summer's end. An amended Janssen licence removing most Phase III funding obligations, combined with a royalty financing of up to $71 million, extends Nanobiotix's cash runway into early 2028. The company reported EUR 32.6 million revenue in 2025, reduced R&D spending to EUR 23.1 million, and EUR 52.8 million cash at year-end.

INACTIVE